Effect of Patient Body Mass, Age, and Renal Function on the Assessment of Cerebrovascular Reactivity During the Acetazolamide Challenge
Clinical Neuroimaging · 2025
DOI: 10.1002/neo2.70017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Neuroimaging, 2025. Verfasst von Rahim Ismail und 7 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Cerebrovascular reactivity (CVR) is a blood flow index which reflects locoregional vascular health in the brain. CVR is measured using MRI with an acetazolamide (AZM) challenge. While 1000 mg of AZM is often used, there is no clear consensus on dosing. We postulate the physiologic variables—age, creatinine, and weight—may impact variation in CVR dynamics, leading to poor study reliability in different patient groups. The present study reviewed patients who underwent AZM challenge MRI examinations at our institution from 2014 to 2022.
Methods
Changes in CVR were evaluated at 5 and 10 min post‐AZM challenge as function of weight, BMI, age, and creatinine. Univariable data was analyzed using Pearson correlation coefficient.
Results
Forty‐nine patients were included in this retrospective review. Forty‐seven percent of patients identified as female, with a mean age of 55 ± 13 years, a mean BMI of 29 ± 6 kg/m 2 , and mean creatinine clearance of 0.96 ± 0.32 mg/dL. BMI was found to be significantly negatively associated with AZM response at 5 min ( r = −0.63, p = 0.002) and 10 min ( r = −0.44, p = 0.045) post‐AZM challenge. However, the present study did not demonstrate changes to CVR by creatinine or age.
Conclusions
CVR is underestimated with increasing body mass, possibly explained by undersaturation of carbonic anhydrase with current standardized dosages. Ubiquitous weight‐based dosing would be a superior and more reproducible predictor for CVR than standardized regimens, particularly at BMI extremes where CVR variability is significant.
Zitieren
APA
Ismail, R., Szekeres, D., George, D., Schartz, D., Manganaro, M., Williams, Z., Bender, M., & Wang, H. (2025). Effect of Patient Body Mass, Age, and Renal Function on the Assessment of Cerebrovascular Reactivity During the Acetazolamide Challenge. Clinical Neuroimaging. https://doi.org/10.1002/neo2.70017
Vancouver
Ismail R, Szekeres D, George D, Schartz D, Manganaro M, Williams Z, et al. Effect of Patient Body Mass, Age, and Renal Function on the Assessment of Cerebrovascular Reactivity During the Acetazolamide Challenge. Clinical Neuroimaging. 2025. doi:10.1002/neo2.70017
BibTeX
@article{Ismail2025,
author = {Ismail, Rahim and Szekeres, Denes and George, Derek and Schartz, Derrek and Manganaro, Mark and Williams, Zoe and Bender, Matthew and Wang, Henry},
title = {Effect of Patient Body Mass, Age, and Renal Function on the Assessment of Cerebrovascular Reactivity During the Acetazolamide Challenge},
journal = {Clinical Neuroimaging},
year = {2025},
doi = {10.1002/neo2.70017}
}
EUVIMED